JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266496

Human TRIP13 (PCH2) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TRIP13 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

16E1-BP, HPV16 E1 protein-binding protein, Homo sapiens HPV16 E1 protein binding protein mRNA complete cds, Human papillomavirus type 16 E1 protein-binding protein, Pachytene checkpoint protein 2 homolog, TR-interacting protein 13, TRIP-13, TRP13_HUMAN, Thyroid hormone receptor interactor 13, Thyroid receptor-interacting protein 13

1 Images
Sanger Sequencing - Human TRIP13 (PCH2) knockout HEK-293T cell line (AB266496)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRIP13 (PCH2) knockout HEK-293T cell line (AB266496)

Homozygous : Insertion of the selection cassette in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266496-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266496-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266496 Human TRIP13 (PCH2) knockout HEK-293T cell line", "number":"AB266496-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266496-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266496-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266496 Human TRIP13 (PCH2) knockout HEK-293T cell line", "number":"AB266496-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266496-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266496 Human TRIP13 (PCH2) knockout HEK-293T cell line", "number":"AB266496-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266496-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266496 Human TRIP13 (PCH2) knockout HEK-293T cell line", "number":"AB266496-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TRIP13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRIP13 also known as PCH2 is a protein involved in the regulation of chromosome dynamics during meiosis and mitosis. It is approximately 48 kDa in size. TRIP13 plays an important role in promoting the disassembly of the synaptonemal complex and ensuring proper chromosome segregation. This protein is expressed in various tissues but shows higher levels in testis suggesting its importance in reproductive cell division.
Biological function summary

TRIP13 contributes to efficient cell cycle progression by participating in the spindle assembly checkpoint (SAC). It forms part of the mitotic checkpoint complex ensuring that chromosomes are correctly attached to the spindle microtubules before progression through mitosis. TRIP13 works in conjunction with other proteins like MAD2 and BUB1 to maintain genomic stability.

Pathways

TRIP13 is involved in the cell cycle control and DNA repair pathways. It influences the mitotic spindle checkpoint interacting with proteins such as MAD2 which ensures that cells do not proceed to anaphase until all chromosomes reach proper alignment. TRIP13 also plays a role in homologous recombination repair by regulating the processing of recombination intermediates.

TRIP13 has been implicated in cancer and infertility. Its overexpression or mutation has been linked to tumor progression and resistance to certain chemotherapeutic agents due to its role in chromosome segregation and genomic stability. Additionally TRIP13 dysfunction may contribute to infertility through its impact on meiosis with potential interactions with proteins involved in reproductive processes such as SYCP3.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com